The filing states the company is a clinical stage company and has not generated any product revenues to date. Its programs include gene therapies for ophthalmology and for central nervous system conditions, supported by collaborations with Eli Lilly and with the Hologen-linked Reogen entity.
On the call, management said it had asked investors in August to measure it on three items: contracted power, contracted annualizedRecurring Revenueon live compute, and capacity brought into service.
On the call, management said total revenues were USD 15.7 million, an increase of 11.1% from USD 14.2 million in the third quarter of 2025.
Revenue was USD 3,461 thousand, against USD 1,924 thousand, with more than 90% of revenue coming from the U.S. government. Cost of revenue was USD 5.2 million, against USD 3.9 million, resulting in a gross loss of USD 1.8 million, against USD 2.0 million.
Third-quarter hardware revenue was USD 575 thousand, against USD 853 thousand a year earlier. Software revenue was USD 879 thousand, against USD 615 thousand, and services revenue was USD 51 thousand, against USD 106 thousand. Total revenue was USD 1,505 thousand, against USD 1,574 …
Revenues were USD 3,775,429, against USD 3,100,018. Cost of revenues was USD 451 thousand, against USD 598 thousand, and gross profit was USD 3.3 million, against USD 2.5 million. Le Mans Ultimate accounted for approximately 75.1% of total revenue, against 75.4% a year earlier.
The quarterly filing shows revenue increased by USD 488.7 million to USD 1,241.8 million, from USD 753.1 million in the third quarter of 2025. Adjusted EBITDA was USD 173 million, a margin of 13.9%, and management described it as record performance for the business.
The company reported total revenue of negative USD 1.9 million. Revenue from contracts with customers was USD 3.9 million, and revenue outside the scope of ASC 606 included derivative revenue of negative USD 5.8 million. The filing notes that results of the legacy healthcareBusinessare …
Nebius AI Cloud revenue was USD 973.8 million, up 643%, and accounted for approximately 99% of group revenue. Group adjusted EBITDA was USD 465.8 million, against negative USD 5.2 million a year ago and USD 236.2 million in the second quarter.
The filing states that total revenues were USD 0.5 million and USD 1.6 million for the three and nine months ended September 30, 2026, against USD 0.4 million and USD 1.5 million in the same periods of 2025.